High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer - PubMed (original) (raw)
. 2001 Jul 15;61(14):5407-14.
Affiliations
- PMID: 11454684
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer
J A Foekens et al. Cancer Res. 2001.
Abstract
Vascular endothelial growth factor (VEGF), a potent angiogenic factor, has been reported to be associated with a poor prognosis in primary breast cancer and in several other cancer types. In the present study, we have measured with ELISA the levels of VEGF in cytosolic extracts of 845 primary breast tumors of patients who developed a recurrence during follow-up. All of the patients received tamoxifen (n = 618) or cyclophosphamide, methotrexate, 5-fluorouracil (CMF) or 5-fluorouracil, Adriamycin, cyclophosphamide (FAC) chemotherapy (n = 227) as first-line systemic therapy after diagnosis of advanced disease. VEGF levels were not related to age or menopausal status but were negatively related to the cytosolic levels of estrogen receptor and progesterone receptor (P < 0.0001). In patients who relapsed within 1 year after primary surgery, tumor VEGF levels were higher than in patients who showed a longer disease-free interval (P = 0.0005). In patients with a first relapse in the viscera, VEGF levels were higher compared with those that relapsed to the bone or soft tissue (P = 0.0004). In univariate analysis for response to first-line tamoxifen therapy, patients with high or intermediate levels showed a poor rate of response, compared with patients with low tumor-VEGF levels (P = 0.0001). Similarly, in multivariate analysis for response to tamoxifen treatment, corrected for age, site of relapse, disease-free interval, and estrogen receptor and progesterone receptor status, VEGF status was an independent predictive factor (P = 0.009). In concordance, higher levels of VEGF were associated with a short progression-free survival and postrelapse overall survival (both, P < 0.0001). On first-line chemotherapy, the rate of response decreased with higher tumor levels of VEGF, both in univariate (P = 0.003) and in multivariate analysis (P = 0.004). Furthermore, higher VEGF levels were associated with a short progression-free survival (P = 0.003) and postrelapse overall survival (P = 0.001). In conclusion, the tumor VEGF level is an important independent marker that predicts a poor efficacy of both tamoxifen and chemotherapy in advanced breast cancer. Knowledge of the tumor level of VEGF might be helpful in selecting individual patients who may benefit from treatments with antiangiogenic agents combined with conventionally used drugs.
Similar articles
- Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M. Gasparini G, et al. Cancer J Sci Am. 1999 Mar-Apr;5(2):101-11. Cancer J Sci Am. 1999. PMID: 10198732 Clinical Trial. - Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA. Berns EM, et al. Clin Cancer Res. 2003 Apr;9(4):1253-8. Clin Cancer Res. 2003. PMID: 12684392 - Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma.
Manders P, Beex LV, Tjan-Heijnen VC, Span PN, Sweep CG. Manders P, et al. Cancer. 2003 Nov 15;98(10):2125-32. doi: 10.1002/cncr.11764. Cancer. 2003. PMID: 14601081 - Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB. Hagemeister FB. Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review. - The biology of breast cancer in older women.
Clark GM. Clark GM. J Gerontol. 1992 Nov;47 Spec No:19-23. J Gerontol. 1992. PMID: 1430878 Review.
Cited by
- Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review.
Leitch IM, Gerometta M, Eichenbaum D, Finger RP, Steinle NC, Baldwin ME. Leitch IM, et al. Ophthalmol Ther. 2024 Jul;13(7):1857-1875. doi: 10.1007/s40123-024-00973-4. Epub 2024 Jun 1. Ophthalmol Ther. 2024. PMID: 38824253 Free PMC article. Review. - The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives.
Żak K, Satora M, Skrabalak I, Tarkowski R, Ostrowska-Leśko M, Bobiński M. Żak K, et al. Cancers (Basel). 2024 Mar 5;16(5):1063. doi: 10.3390/cancers16051063. Cancers (Basel). 2024. PMID: 38473419 Free PMC article. Review. - Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis.
Wang L, Liu WQ, Broussy S, Han B, Fang H. Wang L, et al. Front Pharmacol. 2024 Jan 4;14:1307860. doi: 10.3389/fphar.2023.1307860. eCollection 2023. Front Pharmacol. 2024. PMID: 38239196 Free PMC article. Review. - TGF-β1 activates neutrophil signaling and gene expression but not migration.
Hein LE, SenGupta S, Gunasekaran G, Johnson CN, Parent CA. Hein LE, et al. PLoS One. 2023 Sep 8;18(9):e0290886. doi: 10.1371/journal.pone.0290886. eCollection 2023. PLoS One. 2023. PMID: 37682817 Free PMC article. - Features of VEGF and IL-6 expression in patients with inflammatory breast cancer considering molecular-biological characteristics.
Smolanka II, Bagmut IY, Movchan OV, Sheremet MI, Bilyi OM, Lyashenko AO, Dosenko IV, Loboda AD, Ivankova OM, Kolisnyk IL. Smolanka II, et al. J Med Life. 2023 Jan;16(1):153-159. doi: 10.25122/jml-2022-0172. J Med Life. 2023. PMID: 36873124 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials